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Abstract
Background: Colorectal cancer is frequent in the developed countries, with a cancer-speciﬁc
mortality rate of 33%. Different biomarkers are associated with overall survival and the predic-
tion of monoclonal treatment effectiveness. The presence of mutations in the K-ras oncogene
alters the response to target therapy with cetuximab and could be an independent prognostic
factor.
Aims: To analyze the difference in survival between patients with mutated K-ras and those with
K-ras wild-type status.
Methods: Thirty-one clinical records were retrospectively analyzed of patients presenting with
colorectal cancer that underwent K-ras sequencing through real-time polymerase chain reaction
within the time frame of 2009 to 2012 at the Hospital de Alta Especialidad de Veracruz of the
Instituto para la Salud y Seguridad Social de los Trabajadores del Estado (HAEV-ISSSTE). Survival
analysis for patients with and without K-ras mutation was performed using the Kaplan Meier
method. Contrast of covariates was performed using logarithmic transformations.
Results: No statistically signiﬁcant difference was found in relation to survival in the patients
with mutated K-ras vs. those with K-ras wild-type (P = .416), nor were signiﬁcant differences
found when analyzing the covariants and survival in the patients with mutated K-ras: ECOG scale
(P = .221); age (less than, equal to or greater than 65 years, P = .441); clinical stage according
to the AJCC (P = .057), and primary lesion site (P = .614). Please cite this article as: Cabrera-Mendoza F, Gainza-Lagunes S, Castan˜eda-Andrade I, Castro-Zárate A. Relevancia clínica del oncogén
-ras en cáncer de colon, experiencia en una población mexicana. Revista de Gastroenterología de México. 2014;79:166--170.
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Conclusions: No relation was found between the K-ras oncogene mutation and reduced survival,
in contrast to what has been established in the international medical literature. Further studies
that include both a larger number of patients and those receiving monoclonal treatment, need
to be conducted. There were only 5 patients in the present study that received cetuximab,
resulting in a misleading analysis.
© 2014 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. All
rights reserved.
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Relevancia clínica del oncogén K-ras en cáncer de colon, experiencia en una
población mexicana
Resumen
Introducción: El cáncer de colon es frecuente en los países desarrollados, con una mortalidad
especíﬁca del 33%. Diversos biomarcadores son asociados a la sobrevida global de los pacientes
o predicen el efecto del tratamiento monoclonal. La presencia de mutaciones en el oncogén
K-ras afecta la respuesta a terapia blanco con cetuximab, y podría mostrar valor pronóstico de
manera independiente.
Objetivos: Analizar la diferencia en la supervivencia de pacientes K-ras mutados y en estado
nativo.
Métodos: Se analizaron retrospectivamente 31 expedientes clínicos de pacientes con cáncer
de colon con secuenciación de K-ras utilizando reacción en cadena de polimerasa en tiempo
real realizados desde el an˜o 2009 y hasta 2012 en el Hospital de Alta Especialidad de Veracruz
del Instituto para la Salud y Seguridad Social de los Trabajadores del Estado (HAEV-ISSSTE). Se
analizó la supervivencia entre los pacientes con mutación y aquellos que no la tienen usando el
método de Kaplan-Meier; las covariables se contrastaron usando transformación logarítmica.
Resultados: No se halló una diferencia signiﬁcativa en la sobrevida de los pacientes en los que
se encontró K-ras mutado versus K-ras nativo (p = 0.416). Al analizar covariables y supervivencia
de los pacientes K-ras mutados, tampoco se obtuvieron diferencias signiﬁcativas: escala ECOG
(p = 0.221); edad (<menor a> o <igual o mayor a> 65 an˜os, p = 0.441); estadio clínico según AJCC
(p = 0.057); sitio de lesión primaria, p = 0.614.
Conclusiones: No se encontró relación entre la mutación del oncogén K-ras y disminución en la
sobrevida, a diferencia de lo establecido en la literatura. Es importante realizar estudios con un
mayor número de pacientes y que se incluya el tratamiento monoclonal, que, en el presente,
fueron solo 5 y su análisis es inverosímil.
© 2014 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A.
Todos los derechos reservados.
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high cost it is reserved for a speciﬁc group of patients. AIntroduction
It has been stated that one million persons worldwide
develop colorectal cancer each year, resulting in a cancer-
speciﬁc mortality rate in the developed countries that nears
33%, only behind the mortality rate for lung cancer, which is
13% in Mexico. In 2002, 108,064 new cases were reported
in Mexico, representing a 50% increase in incidence over
a period of 25 years.1--3 The etiology of this neoplasia is
complex and includes a relation between environmental
and genetic factors. The Kirsten Rat Sarcoma Viral Homolog
(K-ras) oncogene encodes for a guanosine triphosphate
(GTP)-binding protein (GTPase) that can mutate at very
early stages of tumor development; it has been reported
that 35 to 42% of adenomas possess a mutation in the K-ras
gene, which promotes hyperplastic growth of the colonic
epithelium, aberrant morphology in the crypt foci, tumor
b
t
prowth, progression, and local invasion and the formation
f metastases.4,5 There are various techniques for detecting
hese mutations and direct sequencing of a PCR product is
he method of choice, resulting in the so-called mutated K-
as and the mutated codon, or if there is no mutation, it is
nown as the wild-type K-ras.6--11
In relation to colorectal cancer management, initial
reatment should be surgical with the intention to cure; the
ole of adjuvant therapy is limited by the modest increase
n survival, and is considered for patients with clinical, his-
ologic, and molecular high-risk recurrence factors.12 The
ddition of biologic therapy is on the rise because of its
eneﬁts over conventional cytotoxic therapy, but due to itsroad review of the subject 13 concluded that K-ras sta-
us is an independent outcome factor, given that patients
resenting with wild-type K-ras live longer and beneﬁt
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ore from monoclonal treatment; clinical trials such as
RYSTAL14 and OPUS15 found that these patients had greater
reatment response, progression-free survival, and overall
urvival than those patients with mutated K-ras in groups
ndergoing conventional chemotherapy and chemotherapy
lus monoclonal therapy. The evidence in recent studies,
ith respect to mutational status, tumor stage, and survival
ate in patients under different treatment regimens showed
hat the detected mutations (especially at codon 12) con-
erred a worse outcome, as did sudden and aggressive liver
etastases. The drug cetuximab is a monoclonal antibody
hat inhibits the epidermal growth factor receptor (EGFR)
nd is currently the biologic therapy of choice for colorectal
ancer. Its use is reserved for wild-type K-ras patients only
nd is associated with other drugs such as capecitabine and
xaliplatin (XELOX regimen) or folinic acid and oxaliplatin
FOLFOX regimen).16,17 It is important to know the clinical
ifferences between the mutated and non-mutated groups
n the local population, given that their study in the Mex-
can population has been very limited and its relevance to
linical decision-making has been pointed out and reported
n publications in other countries. The primary aim of the
resent study was to conﬁrm whether there was a difference
n survival related to the ﬁnding of mutations and if it was
odiﬁed by other variables, in the same manner as has been
escribed in the abovementioned international literature.
ethods
retrospective, comparative, and analytic low-risk study
as conducted in accordance with the 2008 Declaration
f Helsinki and the Health Research Regulation of the
eneral Health Law. Access to the medical records of our
atients was authorized by the general administration
fﬁce of the Hospital de Alta Especialidad de Veracruz
hat belongs to the Instituto para la Salud y Seguridad
ocial de los Trabajadores del Estado (HAEV-ISSSTE) and by
he Bioethics Committee of the Universidad Veracruzana.
igned statements of informed consent for the study were
ot required given that the patients were not operated on
r harmed in any way. The identity of each patient was
rotected through the use of numerical codes. We analyzed
he data of the clinical case records of adult patients
ithin the HAEV-ISSSTE health system using the following
nclusion criteria: histopathologic diagnosis of colorectal
ancer, K-ras sequencing through PCR (mutated or wild-type
-ras), length of time of survival in months, acceptance of
edical and surgical treatment in the coadjuvant modality,
o clinical suspicion of familial colorectal cancer, and the
nclusion of age (under 65 years or 65 years and older), sex,
linical stage (I to IV according to the AJCC), and ECOG
cale (0 to 5). The study period encompassed 3 years, from
anuary 1, 2009, the date in which K-ras sequencing was
egun in the HAEV-ISSSTE, to December 31, 2012, taking
nto account all the sequencings carried out during that
eriod. The patients that abandoned treatment or follow-up
y the oncology service, whose recurrence through imaging
tudies or whose death were not corroborated and/or whose
linical records did not mention all the inclusion criteria,
ere excluded from the study. The descriptive data were:
he number of mutations and their distribution in the
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bovementioned co-variables, the relation of the mutations
o the deaths, and the presence of metastasis; these were
nalyzed through the Pearson chi-square test using the
pi-Info 7.1.3 software. The survival rate in months was
ompared between the patients presenting with wild-type
-ras or mutated K-ras statuses using the Kaplan-Meier
ethod and the data was represented through graphs. The
og-Rank method was used to compare the differences in
he survival results between the wild-type K-ras and the
utated K-ras and their distribution in the co-variables.
esults
total of 63 K-ras sequencings were carried out through
he real-time PCR technique at the HAEV-ISSSTE during the
bovementioned study period. A total of 31 cases were
nrolled; the other 32 were excluded due to incomplete
edical records. A total of 61.3% (n = 19) of the patients
eceived an initial regimen with XELOX and 38.7% (n = 12)
ith FOLFOX; 38.7% of the patients also received radio-
herapy. Only 5 of the total number of patients received
etuximab as adjuvant therapy. Table 1 shows the clinical
tage distribution and the ECOG functional evaluation.
Twelve (38.7%) patients presented with one or various
utations in the K-ras oncogene sequencing, all of which
ere located at codon 12; 4 patients had additional muta-
ions at codon 13. Metastasis was documented in 7 (58.3%)
ases and there were 4 (33.3%) deaths. Nineteen (61.3%)
atients presented with wild-type K-ras, 9 (42.1%) of whom
rogressed to metastatic disease and 3 (15.7%) of whom
ied. The results of an initial analysis of the K-ras muta-
ions with the presence of metastasis (p = 0.82) or deaths
p = 0.48) were not statistically signiﬁcant. The length of
ime of survival in general had a mean value of 16.77± 9.90
onths. Mean survival in the wild-type K-ras patients was
6.31± 10.50 months; in contrast the patients with mutated
-ras had a mean survival of 17.5± 9.27 months. The length
f time of survival and the K-ras status were compared
sing the Kaplan-Meier method and there was no statisti-
al signiﬁcance (p = 0.416) (ﬁg. 1). The co-variables were
ontrasted using the Log-Rank method and the numerical
esults are summarized in Table 1; none of the results were
igniﬁcant. Only 5 patients were in treatment with cetux-
mab, all of them with wild-type K-ras, and they had a mean
urvival of 10± 3 months and a mean recurrence-free time
f 16.6± 10.2 months. Anecdotically, one patient received
reatment with cetuximab, despite presenting with mutated
-ras, and had one of the longest survival periods of this
eport (26 months).
iscussion
he percentages of the mutational ﬁndings and distribution
haracteristics by age, sex, and primary lesion site of
he present study population were very similar to those
eported in the literature. The RASCAL II study,18 and other
ecent smaller studies, concluded that the presence of
-ras mutations were associated with a lower survival rate,
ompared with wild-type K-ras patients, and their risk
atios with greater statistical weight were reported in more
dvanced clinical stages (Dukes C); it was also reported that
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Table 1 Distribution of the population characteristics, number of mutations, and their comparison in relation to survival.
Co-variables n % # of mutations
per group
Length of survival
(months)
p values
by Log-Rank
Age/years
≥65 15 48.6 7 M: 19.3± 9.2
NM: 15.1± 10.5
0.441
<65 16 51.4 5 M: 17.6± 12.2
NM: 15.6± 10.5
Sex
Men 15 48.6 5 M 20.4± 7.1
NM 17.60± 11.6
0.53
Women 16 51.4 7 M 15.4± 10.2
NM 14.8± 10.5
Clinical stagea
I 3 9.7 1 M 4
NM 33.6± 7.5
0.057
II 11 35.5 3 M 17± 7
NM 19.5± 10.5
III 7 22.6 3 M 18.3± 11.9
NM 14.5± 10.7
IV 10 32.3 5 M 20± 10.2
NM 5
ECOG scalea
0 5 16.1 0 -a 0.221
1 11 36.5 3 M 24± 9.8
NM 22.8± 10.5
2 10 32.3 7 M 16.2± 9.4
NM 7
3 2 6.5 1 M 11
NM23
4 3 9.7 1 M 11
NM 10± 6
5 0 - - - *
Primary lesion siteb
Colon 18 58.1 6 M 13.1± 9.8
NM 15.8± 10.5
0.614
Rectum 13 41.9 6 M 21.8± 10.6
NM 17.1± 10.9
With metastasis
16 51.4 7 M 19.± 9.4
NM 14.3± 10.5
0.16
M: mutated K-ras; NM: wild-type K-ras.
a Due to the reduced number of cases with mutations, the statistical analysis was inappropriate.
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mb Adenocarcinoma.
the mutations at codon 12 conferred aggressive biology.19
However, studies conducted with a similar methodology, but
a notably lower number of patients,11,20 in which the K-ras
sequencing was carried out with the method of choice and
in a local population, did not ﬁnd any difference in survival
between the mutated and wild-type groups, nor was it
inﬂuenced by the co-variables. Carrying out sequencing on
all the patients with colorectal cancer is a very important
part of directing treatment; it has been consistently
demonstrated that the mutations in exon 1 of this oncogene
make treatment with cetuximab less effective, modifying
i
r
a
wurvival.21 In the present study, the number of patients
reated with cetuximab was not large enough for a useful
tatistical test to be performed. Sufﬁce it to say that
urvival was very poor (10± 3 months), as well as anecdotal
n one case in which the K-ras mutation was corroborated in
second sequencing, and survival was above the mean (26
onths). The abovementioned is a problem for researchersn the so-called emerging countries because, even in refer-
al centers, K-ras sequencing is not carried out routinely
nd monoclonal treatment is not given to all the patients
ith wild-type K-ras, due to the high cost of both.
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2Figure 1 Kaplan-Meier method.
onclusions
n the present pilot study, no relation was found between
he presence of mutated K-ras and progression to metastasis
r association with a greater proportion of deaths, in con-
rast to what has been reported in the medical literature.
urther studies with a larger number of patients receiv-
ng monoclonal treatment need to be conducted in order
o extrapolate the published information to the Mexican
opulation.
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